Want to see IN:INDOCO full AI Analyst Report?
INDOCO Stock Chart & Stats
₹238.85
₹4.72(1.94%)
At close: 4:00 PM EDT
₹238.85
₹4.72(1.94%)
Day’s Range― - ―
52-Week Range₹163.70 - ₹317.10
Previous CloseN/A
Volume80.97K
Average Volume (3M)68.19K
Market Cap
₹23.23B
Enterprise Value₹25.64B
Total Cash (Recent Filing)₹329.90M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)862.2
Beta1.09
Next Earnings
Nov 05, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)0.29
Shares Outstanding92,303,604
10 Day Avg. Volume79,245
30 Day Avg. Volume68,189
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)1.55
Price to Sales (P/S)0.79
P/FCF Ratio-12.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.48
Revenue Forecast (FY)₹20.51B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive revenue growth indicates that product demand and commercial reach remain intact despite recent profitability pressure. Continued expansion in sales can provide a foundation for recovery if management improves cost control and converts the existing top-line momentum into stronger operating earnings.
Gross MarginA roughly 41% gross margin provides an economic base for the formulations and API portfolio, showing that products retain meaningful value after direct production costs. The improvement versus FY2024 could support earnings recovery if operating expenses and other costs are brought under control.
Diversified Pharma PlatformIndoco's combination of formulations, APIs, branded domestic products, exports, manufacturing, and R&D creates several routes to generate revenue. Its presence across therapy areas and geographies can support resilience and broaden growth opportunities beyond any single product or market.
Bears Say
Sustained LossesTwo consecutive years of net losses show that revenue growth is not currently translating into sustainable shareholder earnings. The negative net margin reduces internal funding capacity and leaves the business more exposed to execution problems until operating performance and cost absorption improve.
Higher LeverageThe sharp increase in debt relative to equity has reduced financial flexibility while profitability is weak. Higher leverage can make it harder to fund expansion, absorb operating setbacks, or manage obligations comfortably, increasing the importance of a timely recovery in earnings and returns.
Negative Free Cash FlowDeeply negative free cash flow indicates that operating cash generation has not covered investment and other cash needs in the latest two years. This weakens self-funding capacity, increases reliance on financing or asset resources, and highlights ongoing execution risk around capital deployment.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹317.10 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹23.23B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on Jul 28, 2026. The company reported ₹7.1 earnings per share for the quarter, beating the consensus estimate of -₹3.6 by ₹10.7.
Is Indoco Remedies Limited overvalued?
According to Wall Street analysts Indoco Remedies Limited’s price is currently Overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate is 0.9.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,303,604 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of ₹7.1 in its last earnings report, beating expectations of -₹3.6. Following the earnings report the stock price went down -7.931%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indoco Remedies Limited
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Hikal Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―









